Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04126070 |
Recruitment Status :
Active, not recruiting
First Posted : October 14, 2019
Last Update Posted : April 24, 2024
|
Sponsor:
Xiao X. Wei, MD
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Xiao X. Wei, MD, Dana-Farber Cancer Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | June 30, 2024 |
Estimated Study Completion Date : | June 30, 2025 |